ARPC1B and familial pancreatic carcinoma: These findings suggest that ARPC1B+ CSCs are enriched in gemcitabine‐resistant cases and may serve as a potential biomarker of poor prognosis and a promising therapeutic target for gemcitabine‐resistant pancreatic cancer.